JP2019504031A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019504031A5 JP2019504031A5 JP2018533051A JP2018533051A JP2019504031A5 JP 2019504031 A5 JP2019504031 A5 JP 2019504031A5 JP 2018533051 A JP2018533051 A JP 2018533051A JP 2018533051 A JP2018533051 A JP 2018533051A JP 2019504031 A5 JP2019504031 A5 JP 2019504031A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- inhibitor
- gpv
- bleeding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 208000032843 Hemorrhage Diseases 0.000 claims 12
- 230000000740 bleeding effect Effects 0.000 claims 12
- 239000003112 inhibitor Substances 0.000 claims 9
- 101000926072 Varicella-zoster virus (strain Dumas) Envelope glycoprotein C Proteins 0.000 claims 8
- 239000012634 fragment Substances 0.000 claims 5
- 239000000701 coagulant Substances 0.000 claims 4
- 102100038411 Platelet glycoprotein V Human genes 0.000 claims 3
- 102000008186 Collagen Human genes 0.000 claims 2
- 108010035532 Collagen Proteins 0.000 claims 2
- 101001033026 Homo sapiens Platelet glycoprotein V Proteins 0.000 claims 2
- 208000013544 Platelet disease Diseases 0.000 claims 2
- 101710195077 Platelet glycoprotein V Proteins 0.000 claims 2
- 208000014759 blood platelet disease Diseases 0.000 claims 2
- 229920001436 collagen Polymers 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 claims 1
- 208000016988 Hemorrhagic Stroke Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 238000004220 aggregation Methods 0.000 claims 1
- 230000002776 aggregation Effects 0.000 claims 1
- 230000003471 anti-radiation Effects 0.000 claims 1
- 208000034158 bleeding Diseases 0.000 claims 1
- 239000003114 blood coagulation factor Substances 0.000 claims 1
- 239000012141 concentrate Substances 0.000 claims 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 claims 1
- 239000004023 fresh frozen plasma Substances 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 239000003634 thrombocyte concentrate Substances 0.000 claims 1
- 206010043554 thrombocytopenia Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15202582.1 | 2015-12-23 | ||
| EP15202582.1A EP3184544A1 (en) | 2015-12-23 | 2015-12-23 | Glycoprotein v inhibitors for use as coagulants |
| PCT/EP2016/082572 WO2017109180A1 (en) | 2015-12-23 | 2016-12-23 | Glycoprotein v inhibitors for use as coagulants |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019504031A JP2019504031A (ja) | 2019-02-14 |
| JP2019504031A5 true JP2019504031A5 (cg-RX-API-DMAC10.html) | 2020-01-16 |
Family
ID=55085479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018533051A Pending JP2019504031A (ja) | 2015-12-23 | 2016-12-23 | 血液凝固剤として使用するための糖タンパク質ｖ阻害剤 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20190169307A1 (cg-RX-API-DMAC10.html) |
| EP (2) | EP3184544A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2019504031A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20180095083A (cg-RX-API-DMAC10.html) |
| CN (1) | CN108473581A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2016375162A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3008198A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2017109180A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20260217861A1 (en) | 2022-12-22 | 2026-07-30 | Jjulius-Maximilians-Universität-Würzburg | Antibodies for use as coagulants |
| CN116375859A (zh) * | 2023-06-05 | 2023-07-04 | 北京大学第一医院 | 一种抗vWF/PF4蛋白的单克隆抗体及其应用 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US6083688A (en) * | 1993-07-09 | 2000-07-04 | Cor Therapeutics, Inc | Platelet glycoprotein V gene and uses |
| CA2166872A1 (en) * | 1993-07-09 | 1995-01-19 | Francois Lanza | Platelet glycoprotein v gene and uses |
| CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| EP1972194A1 (en) | 1996-12-03 | 2008-09-24 | Amgen Fremont Inc. | Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| JP3876002B2 (ja) | 1997-04-14 | 2007-01-31 | ミクロメート・アクチエンゲゼルシャフト | 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用 |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| CA2337693A1 (en) * | 1998-08-04 | 2000-02-17 | Cor Therapeutics, Inc. | Transgenic animals having a modified glycoprotein v gene |
| AU1728800A (en) | 1998-11-18 | 2000-06-05 | Genentech Inc. | Antibody variants with higher binding affinity compared to parent antibodies |
| DK1177289T3 (da) * | 1999-05-07 | 2008-08-11 | Sanofi Aventis Deutschland | Rekombinant blodpladecollagenreceptor glycopotein VI og dets farmaceutiske anvendelse |
| US7365168B2 (en) | 2002-10-15 | 2008-04-29 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| EP1673395A1 (en) | 2003-10-15 | 2006-06-28 | PDL BioPharma, Inc. | Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig |
| WO2005123780A2 (en) | 2004-04-09 | 2005-12-29 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
| GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
-
2015
- 2015-12-23 EP EP15202582.1A patent/EP3184544A1/en not_active Withdrawn
-
2016
- 2016-12-23 EP EP16826340.8A patent/EP3394101A1/en not_active Withdrawn
- 2016-12-23 WO PCT/EP2016/082572 patent/WO2017109180A1/en not_active Ceased
- 2016-12-23 KR KR1020187021268A patent/KR20180095083A/ko not_active Withdrawn
- 2016-12-23 CN CN201680075538.6A patent/CN108473581A/zh active Pending
- 2016-12-23 AU AU2016375162A patent/AU2016375162A1/en not_active Abandoned
- 2016-12-23 JP JP2018533051A patent/JP2019504031A/ja active Pending
- 2016-12-23 US US16/065,300 patent/US20190169307A1/en not_active Abandoned
- 2016-12-23 CA CA3008198A patent/CA3008198A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Balagholi et al. | Potential of therapeutic plasmapheresis in treatment of COVID-19 patients: Immunopathogenesis and coagulopathy | |
| Ding et al. | Emerging role of HMGB1 in lung diseases: friend or foe | |
| Heinbockel et al. | Preclinical investigations reveal the broad-spectrum neutralizing activity of peptide Pep19-2.5 on bacterial pathogenicity factors | |
| Samson et al. | Influenza virus resistance to neuraminidase inhibitors | |
| Cong et al. | Plasma membrane wounding and repair in pulmonary diseases | |
| Pires et al. | Hyper‐inflammation and complement in COVID‐19 | |
| JP2015529225A5 (cg-RX-API-DMAC10.html) | ||
| ME03794B (me) | Derivati pirazola kao inhibitori kalikreina plazme | |
| JP2010285439A5 (cg-RX-API-DMAC10.html) | ||
| HRP20220355T1 (hr) | Postupci za liječenje infekcija coronaviridae | |
| Zhu et al. | High mobility group box 1 protein as a potential drug target for infection-and injury-elicited inflammation | |
| JP2015502389A5 (cg-RX-API-DMAC10.html) | ||
| FI4374873T3 (fi) | Aine käytettäväksi silmäsairauksien hoidossa tai ehkäisyssä | |
| JP2015512406A5 (cg-RX-API-DMAC10.html) | ||
| JP2012518624A5 (cg-RX-API-DMAC10.html) | ||
| JP2016512218A5 (cg-RX-API-DMAC10.html) | ||
| JP2014515763A5 (cg-RX-API-DMAC10.html) | ||
| RU2015134422A (ru) | Применение левоцитиризина и монтелукаста при лечении васкулита | |
| JP2011527301A5 (cg-RX-API-DMAC10.html) | ||
| JP2015511625A5 (cg-RX-API-DMAC10.html) | ||
| JP2015512927A5 (cg-RX-API-DMAC10.html) | ||
| JP2015513535A5 (cg-RX-API-DMAC10.html) | ||
| Amoafo et al. | Platelet P2Y12 signalling pathway in the dysregulated immune response during sepsis | |
| JP2013525310A5 (cg-RX-API-DMAC10.html) | ||
| JP2015524823A5 (cg-RX-API-DMAC10.html) |